Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 8/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4933035 | 1.00 | ESR1 (0.44) | ESR1ESR2HSP90AA1HPGDRAB9A | |
| SCHEMBL4932010 | 0.68 | MAPT (0.48) | ESR1ESR2HSP90AA1RAB9ASMN1; SMN2 | |
| SCHEMBL11408549 | 0.68 | MAPT (0.70) | HPGDSMN1; SMN2MAOBMAPTKMT2A | |
| SCHEMBL11408547 | 0.68 | MAPT (0.70) | HPGDSMN1; SMN2MAOBMAPTKMT2A | |
| SCHEMBL5992116 | 0.68 | ESR1 (0.59) | ESR1ESR2HSP90AA1HPGDRAB9A | |
| SCHEMBL11648565 | 0.67 | KMT2A (0.49) | RAB9AMAOBMAPTKMT2AALDH1A1 | |
| SCHEMBL11648567 | 0.67 | KMT2A (0.49) | RAB9AMAOBMAPTKMT2AALDH1A1 | |
| SCHEMBL4933522 | 0.66 | ESR1 (0.72) | ESR1ESR2HSP90AA1 | |
| SCHEMBL11643922 | 0.65 | CA12 (0.44) | ESR1ESR2MAOBMAPTKMT2A | |
| SCHEMBL11643917 | 0.65 | CA12 (0.44) | ESR1ESR2MAOBMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070960-A1 | Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer | AVENTIS PHARMA S.A. (FR) | 2008-03-20 | — | — | US | claimed |
| US-20080070960-A1 | Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer | AVENTIS PHARMA S.A. (FR) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070960-A1 | Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer | UGT2B7, UGT2B17, CYP4X1 | ESR1 2306/4885ESR2 987/4885HSP90AA1 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.